A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases

1

Approximately 20–25% of metastatic cancer patients develop brain metastases, which are more frequent than primary brain tumors.
2

Despite treatment advancements, the incidence of brain metastases is rising, with median survival times ranging from 2 to 21 months.
3

The study developed an in vitro drug-screening platform to identify therapeutic vulnerabilities in primary cultures of brain metastases.
4

Integrating drug response results with genetic alterations may enhance personalized treatment options for brain metastasis patients.
5

Ethical approval was obtained for the study, which involved collecting and analyzing patient-derived tumor samples for research.

Journal Of Neuro-Oncology

by Sebastian Jeising, Ann-Christin Nickel, Johanna Trübel, Jörg Felsberg, Daniel Picard, Gabriel Leprivier, Marietta Wolter, My Ky Huynh, Marlene B. Olivera, Kerstin Kaulich, Lena Häberle, Irene Esposito, Gunnar W. Klau, Julia Steinmann, Thomas Beez, Marion Rapp, Michael Sabel, Sascha Dietrich, Marc Remke, Jan F. Cornelius, Guido Reifenberger, Nan Qin
July 10, 2024

1